Compare CYTK & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | PPC |
|---|---|---|
| Founded | 1997 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.9B |
| IPO Year | 2004 | 1987 |
| Metric | CYTK | PPC |
|---|---|---|
| Price | $64.86 | $41.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 3 |
| Target Price | ★ $82.38 | $46.33 |
| AVG Volume (30 Days) | ★ 2.2M | 912.7K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 20.79% |
| EPS Growth | N/A | ★ 24.34 |
| EPS | N/A | ★ 5.16 |
| Revenue | $87,211,000.00 | ★ $18,351,780,000.00 |
| Revenue This Year | $346.43 | $3.95 |
| Revenue Next Year | $57.69 | $0.51 |
| P/E Ratio | ★ N/A | $7.83 |
| Revenue Growth | ★ 2609.26 | 1.76 |
| 52 Week Low | $29.31 | $35.73 |
| 52 Week High | $70.98 | $57.16 |
| Indicator | CYTK | PPC |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 64.93 |
| Support Level | $60.30 | $38.29 |
| Resistance Level | $65.25 | $40.02 |
| Average True Range (ATR) | 2.82 | 0.95 |
| MACD | 0.14 | 0.17 |
| Stochastic Oscillator | 73.00 | 95.81 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.